文献速递血脂与心血管预防

家族性高胆固醇血症中脂蛋白(a)的新型药物治疗策略

Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
PubMed 文献 · Eur Heart J · 2017-01-01

他汀和依折麦布不降低Lp(a),PCSK9单抗仅降低15-30%,而载脂蛋白(a)反义疗法最高可降90%,联合PCSK9抑制剂或为最佳策略。

要点

  • HeFH患者中约1/3合并Lp(a)升高,显著增加ASCVD残余风险。
  • 他汀和依折麦布不降低Lp(a),PCSK9单抗仅降15-30%。
  • 载脂蛋白(a)反义疗法降Lp(a)可达90%,联合PCSK9抑制剂或为最优策略。

核心结论

  • PCSK9抑制剂联合载脂蛋白(a)反义疗法可能是降低HeFH合并高Lp(a)患者ASCVD残余风险的最佳策略。

研究设计与样本

  • 综述性文章,总结家族性高胆固醇血症中脂蛋白(a)靶向治疗的最新研究进展。

主要发现

  • 高LDL-C与高Lp(a)组合可显著加速早发ASCVD。
  • 他汀和依折麦布不降低Lp(a),PCSK9单抗仅降低15-30%。
  • 载脂蛋白(a)反义疗法在近期试验中显示最高可达90%的Lp(a)降幅。

关键数值与推荐

  • PCSK9单抗适用于未达指南推荐LDL-C目标的HeFH患者,但仅降低Lp(a)15-30%。
  • 载脂蛋白(a)反义疗法在近期试验中显示最高90%的Lp(a)降幅。

临床怎么用

  • 对HeFH患者应关注Lp(a)水平,识别高残余风险者。
  • 对他汀和依折麦布治疗后LDL-C达标但Lp(a)仍高的HeFH患者,可考虑PCSK9单抗。
  • 载脂蛋白(a)反义疗法联合PCSK9抑制剂可能是未来降低残余风险的方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 35 million people worldwide suffer from heterozygous familial hypercholesterolaemia (HeFH), a condition characterized by genetically determined life-long elevation of plasma low-density lipoprotein cholesterol (LDL-C). One in three of these patients also inherit an elevated plasma concentration of lipoprotein (a) [Lp(a)], a lipoprotein particle with atherogenic, inflammatory and prothrombotic properties. Accordingly, the combination of high plasma LDL-C and Lp(a) can markedly accelerate premature atherosclerotic cardiovascular disease (ASCVD). Neither statin nor ezetimibe lowers Lp(a), so that FH patients with high Lp(a) remain at high residual risk of ASCVD. PCSK9 monoclonal antibodies are indicated for HeFH patients not at guideline-recommended LDL-C target, but only lower Lp(a) concentration by 15-30%. Recent trials employing apo(a) antisense therapy show more potent (up to 90%) reductions in plasma Lp(a). The combination of PCSK9 inhibitor and apo(a) antisense therapy appears the optimal strategy for mitigating residual risk of ASCVD in HeFH patients with high Lp(a).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Vuorio A, Watts GF, Kovanen PT, et al. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J. 2017. PMID: 29029165. doi:10.1093/eurheartj/ehx546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。